ONCOLYTICS BIOTECH INC

Oncolytics insider trading sparks optimism—SVP Lee Chan Henry’s August 11 buy shows confidence amid a volatile, bearish market.

Oncolytics CEO’s recent 6,717‑share sale shows routine liquidity planning, not a warning—focus on the company’s pelareorep pipeline and partnership prospects.

Oncolytics Biotech CFO sells 1,157 ADS amid rising insider activity – could signal short‑term price drag before REOLYSIN milestones.

CEO John’s insider sale of 5,146 ADS at $310 each reflects strategic hedging amid Oncolytics’ FDA fast‑track news—investors should watch pelareorep milestones.

CEO Oyler John’s recent buy of 64,628 Oncolytics Biotech ADS signals renewed confidence amid a steep decline, hinting at a strategic shift toward REOLYSIN and AI partnerships.

Oncolytics Biotech insider trades reveal CEO Oyler John’s disciplined 10b‑5‑1 strategy—selling high, buying low—while key clinical milestones loom.

Oncolytics insider sales reveal portfolio rebalancing amid a bullish biotech market—insiders cashing in on gains while the company gears up for Pelareorep’s commercial launch, offering a nuanced view for investors.

Insightful insider‑sale analysis shows ONCOLYTICS’ executives’ routine RSU‑driven trades aren’t a sign of distress, yet investors should watch future divestments and clinical milestones to gauge confidence in the biotech firm.

Oncolytics insider sale: Yi Qingqing liquidates 235 ADS, raising questions on confidence while insiders buy. Monitor pipeline milestones for upside.

Oncolytics Biotech insiders add to their positions, showing confidence in its reovirus therapy while navigating cash‑tight biotech waters.